Opthea Ltd

OPT

Company Profile

  • Business description

    Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company geographically operates Australia and United States.

  • Contact

    650 Chapel Street
    Level 4, Suite 0403
    South YarraVIC3141
    AUS

    T: +61 398260399

    https://www.opthea.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    30 June 2026

    Employees

    34

Stocks News & Analysis

stocks

Our three most overvalued ASX shares

These three companies are trading at a significant premium to our fair value.
stocks

What does big US court decision mean for Google’s parent company Alphabet?

Alphabet shares popped 7% after the ruling on September 2 and have now rallied by around 50% since April.
stocks

Our only 5-star wide moat ASX share

A difficult year but better times ahead.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,126.902.50-0.03%
CAC 407,734.8460.060.78%
DAX 4023,807.13210.150.89%
Dow JONES (US)45,514.95114.090.25%
FTSE 1009,221.4413.230.14%
HKSE25,633.91215.930.85%
NASDAQ21,798.7098.310.45%
Nikkei 22543,643.81625.061.45%
NZX 50 Index13,281.1457.610.44%
S&P 5006,495.1513.650.21%
S&P/ASX 2008,849.605.60-0.06%
SSE Composite Index3,826.8414.330.38%

Market Movers